Publications

Back to Publications

Stay up to date with our literature reviews which are curated by experts to feature the most important publications released each month. Explore our publications for access to concise summary slides for your own use.

Effect of Semaglutide versus Other Glucagon-Like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Head-to-Head, Phase 3, Randomized Controlled Trials

J Diabetes Complications. 2023;37:108529 DOI: 10.1016/j.jdiacomp.2023.108529

GLP-1RAs vary in their abilities to control glycaemia, reduce body weight and improve other cardiometabolic risk factors. A recent systematic review and meta-analysis assessed the efficacy and safety of semaglutide compared with other GLP-1RAs in head-to-head phase 3 RCTs in adults with T2D.

Compared to other GLP-1RAs, semaglutide provided a significantly greater reduction in HbA1c levels by 0.44 %, in fasting plasma glucose by 0.48 mmol/L, in body weight by 2.53 kg and in BMI by 0.91 kg/m2. However, treatment with semaglutide was also associated with significantly greater odds for GI AEs and treatment discontinuation.

Keywords:


LinkedIn